What can cause false-positive antiphospholipid antibody test results?

False-Positive Antiphospholipid Antibody Causes

False-positive antiphospholipid antibody results occur most commonly due to anticoagulant therapy (particularly vitamin K antagonists and DOACs), acute phase reactions, infections, and the presence of non-pathogenic antibodies that lack beta-2-glycoprotein I cofactor dependency.

Primary Causes of False-Positive Results

Anticoagulant Interference

• Vitamin K antagonists (VKA) can cause false-positive lupus anticoagulant (LA) results by prolonging phospholipid-dependent clotting times 11
• Direct oral anticoagulants (DOACs) interfere with LA testing and require pretest removal procedures 1
• Heparin contamination produces false-positive results; samples should be checked for anti-factor Xa activity when thrombin time is prolonged 2
• LA testing should ideally be performed 1-2 weeks after VKA discontinuation (with or without LMWH bridging) 1

Transient Non-Pathogenic Antibodies

• Infection-induced antibodies differ fundamentally from autoimmune aPL in IgG subclass, light chain preference, antibody avidity, and cofactor requirement 3
• These antibodies recognize negatively charged phospholipids but lack the beta-2-glycoprotein I cofactor dependency characteristic of pathogenic antibodies 43
• Acute phase proteins can cause transient positivity 1

Technical and Methodological Issues

• Anticardiolipin (aCL) ELISA has high false-positive rates: Studies show 93% of aCL-positive samples in one cohort were negative for anti-beta-2-glycoprotein I antibodies, indicating non-pathogenic antibodies 5
• Low-titer results near cutoff values (≤10% variation) may fluctuate due to assay imprecision, which has a maximal acceptable limit of 10% 1
• Cross-reactivity: False-positive FVIII antibody ELISA results can occur in patients with LA or antiphospholipid antibodies 6

Pregnancy-Related Fluctuations

• aPL levels decrease during pregnancy: 25% of LA-positive patients become negative in second or third trimester 1
• Factor VIII increases gradually during pregnancy, potentially masking LA presence by shortening APTT 1
• IgG aCL and anti-beta-2-glycoprotein I remain positive through pregnancy in 93% and 85% of cases respectively, but titers are significantly lower in second and third trimesters 1

Thrombosis-Related Changes

• Acute thrombotic events cause antibody titers to decrease due to deposition at the thrombotic site, with subsequent increase after the event 1
• Testing during the acute post-thrombotic phase should be repeated at a distance from the event 1

Critical Diagnostic Pitfalls

Single Test Positivity

A large multicenter study found that 24% of samples from specialized centers with positive LA results were actually false-positives upon central laboratory evaluation 2. These false-positive patients were:

• Significantly older (49.7 vs 45.0 years)
• More often newly diagnosed (66% vs 41%)
• More frequently judged as mild in LA potency (60% vs 25%)
• Had normal anticardiolipin and anti-beta-2-glycoprotein I antibodies more often (82% vs 42%) 2

Confirmation Requirements

Two consecutive positive tests at least 12 weeks apart are mandatory to rule out transient positivity, which is insufficient for APS diagnosis 1. The same antibodies must be positive on repeat testing 1.

Risk Stratification for True vs False Positivity

Higher Likelihood of True Positivity

• Triple positivity (LA + aCL + anti-beta-2-glycoprotein I) or double positivity with concordant isotype 1
• LA detected by both dRVVT and KCT (63% of positive samples) shows significantly stronger potency than single-test positivity 2
• IgG isotype is clinically more relevant than IgM 1
• Persistent medium/high titer (>99th percentile) 1

Higher Likelihood of False Positivity

• Single IgM positivity is regarded as less clinically relevant 1
• Low positive results around cutoff values 1
• Absence of anti-beta-2-glycoprotein I antibodies in aCL-positive samples 5
• Testing during anticoagulation, pregnancy, or acute thrombosis 1

Recommended Approach to Minimize False Positives

Retesting strategy: Equivocal or low-positive results should be repeated to confirm positivity or negativity 1. Retesting is particularly important when:

• Results obtained during VKA treatment
• Double-positive patients (aCL and anti-beta-2-glycoprotein I)
• Testing performed in acute phase 1

Laboratory reporting should include warnings for potential interferences (anticoagulant therapy, acute phase proteins) and results must be interpreted in clinical context with knowledge of anticoagulation status 1.